Skip to content
‹ Back to IndustriesHealthcare

AI Shouldn't Replace Physicists - It Should Give Them Time Back

The article discusses the role of AI in the healthcare industry, emphasizing that AI should enhance the efficiency of physicists rather than replace them. TheraPanacea, founded by mathematician Nico Asperagus, focuses on developing AI platforms to improve efficiency and standardization in healthcare. The aim is for AI to handle routine tasks, allowing professionals more time for complex problem-solving.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Jeanine Mendes ·
Share

Key takeaways

01

AI should be used to enhance the efficiency of physicists rather than replace them.

02

TheraPanacea develops AI platforms for improving efficiency and standardization in healthcare.

03

AI platforms aim to manage routine tasks, allowing professionals more time for complex analysis.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

TheraPanacea was founded in 2017 as a spin-off from the mathematics and computer science department at Paris Leclerc University. Led by CEO and founder Nico Asperagus, a mathematician by training, the company has built an AI platform designed to address efficiency, quality, and standardization across the full radiation oncology workflow, from CT simulation and MR simulation through treatment delivery.

The company's academic origins shape how it operates. TheraPanacea collaborates with institutions including Gustav Roussy, Penn Medicine, and Cleveland Clinic, not only to source training data for its models but to ensure those models are clinically validated before reaching care teams. The organization employs a significant number of scientists and PhD researchers alongside engineers, and it participates actively in academic publishing. That dual identity, part technology company, part research institution, is central to how TheraPanacea positions itself in the market.

Complementing the clinical workflow, not replacing it

A recurring theme in conversations with the TheraPanacea team at the Vancouver event was the importance of fitting AI into existing clinical pathways rather than disrupting them. The goal, as described by company representatives, is to handle more standardized treatment types through automation so that dosimetry and physics staff can redirect their attention to complex or emergent cases. The platform covers auto-contouring and automated planning, areas where incremental time savings can compound into meaningful capacity gains across a busy department.

We don't wanna necessarily replace a traditional pathway. What we wanna do is complement the traditional pathway for those types of treatments that maybe are more standard, so that your dosimetry teams and your physics team can spend more time on those complex or emergent cases. — Steve Andersen, Chief Growth Officer, Head of US, TheraPanacea

To illustrate how far the field has already traveled, one team member pointed to the evolution of treatment planning over roughly two decades. Manual contouring once consumed enormous amounts of clinical time. The introduction of atlas-based libraries changed that baseline, and AI-driven auto-contouring and auto-planning represent the next step in that progression. The argument is that the profession has already absorbed major workflow shifts and is technically and culturally prepared to absorb another.

Validation and staff readiness as prerequisites for adoption

Clinicians at the event were candid about how AI products actually move through their institutions. Adoption is not driven by individual enthusiasm for a given tool. It depends on a structured evaluation process that includes mock testing before any live rollout. As one clinician described it, once a product passes through all of the institutional filters and testing phases, the decision to use it follows naturally.

I just trust my leadership (at Texas Oncology). They evaluate a lot of products. So once that is going through all of the filters, the testing, we do mock testing, and then they roll it out. It's good to go. — Dr. Dana Rosencranz, Chief Medical Physicist, Texas Oncology

That perspective underscores a broader truth about AI adoption in radiation oncology: the technology itself is only part of the equation. Proper education, staff training, and rigorous clinical validation are the conditions that determine whether a tool gets used at scale. For TheraPanacea, the emphasis on academic collaboration and published research is not incidental. It is the mechanism through which the company builds the evidence base that institutions require before committing to a new platform.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

JM
Jeanine MendesMarketing, TheraPanacea
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Why hospitals stagger security upgrades instead of shutting down

Why hospitals stagger security upgrades instead of shutting down

Parabit Systems' Robert Iraggi told A Weekly Bit that hospital security upgrades must be planned and staggered because the building never closes. OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013 against under two in construction, and Joint Commission EP 17 requires an annual worksite analysis. Illinois biometric law adds a consent step for facial recognition.

  • 01OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013; construction, manufacturing and retail each stayed under two.
  • 02Joint Commission EP 17 has required an annual workplace violence worksite analysis since January 2022, and hospitals are expected to act on what it finds—making phased security upgrades easier to document year to year.
  • 03Squire Patton Boggs counted at least 100 Illinois biometric privacy class actions filed in 2025, and Illinois’ BIPA requires notice and consent for collecting biometrics—so a facial-recognition rollout plan should include the notice, consent record, and retention controls before the first camera goes live.

Nov 17, 2026

Sterile processing deviations become the norm without stop-and-document rules

Sterile processing deviations become the norm without stop-and-document rules

Advanced Sterilization Products' Tamara Beeler told Censis Technologies' CtUC 2026 audience that sterile processing deviations harden into norms when departments don’t stop, escalate and document them. She connects ANSI/AAMI ST108:2023 water categories, daily cleaning verification, loaner-tray refusal when sets arrive late or lack IFUs, and root cause analysis when rework repeats on the same device.

  • 01ANSI/AAMI ST108:2023 turned water quality for instrument reprocessing into an enforceable standard; AAMI's earlier TIR34 was guidance with no enforcement behind it.
  • 02Some facilities require loaner trays 48 hours before a case, and ASP's Tamara Beeler says a technician at any level can refuse one that arrives late, undocumented or dirty.
  • 03Rework that returns on the same device is the point at which Beeler wants a root cause analysis opened, with the record kept in the instrument tracking system.

Nov 17, 2026

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea CEO Nikos Paragios says the company's two objectives are to carry best-center radiotherapy quality to every patient and to pick each patient's treatment at the start from multimodal data. A 2026 Nature Communications trial of 500 patients found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902, and Siemens Healthineers CE-marked its own AI contouring in May 2026.

  • 01TheraPanacea's two stated objectives: carry best-center radiotherapy quality to every patient on the globe, and identify each patient's best treatment at the start from imaging and clinical history.
  • 02A 2026 Nature Communications trial of 500 patients across five centers found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902 and cut median contouring time from 55 to 10 minutes, with less variation between centers.
  • 03Siemens Healthineers' Varian business CE-marked AI contouring for Eclipse in May 2026, so Paragios locates TheraPanacea's edge in its team, hospital partnerships and impact focus rather than in the algorithm alone.

Nov 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

JM
Jeanine Mendes

Marketing

TheraPanacea

NA
Nico Asperagus

CEO and Founder

TheraPanacea

Nico Asperagus is a mathematician by training and the CEO and founder of TheraPanacea, a company launched as a spin-off from Paris Leclerc University. He leads efforts in developing AI platforms to improve efficiency, quality, and standardization in healthcare.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512